| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.37 | 6e-13 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | 0.25 | 6e-10 |
| mRNA | neratinib | CTRPv2 | pan-cancer | AAC | 0.24 | 1e-09 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.3 | 9e-09 |
| mRNA | lapatinib | CTRPv2 | pan-cancer | AAC | 0.21 | 4e-08 |
| mRNA | BIBW2992 | CTRPv2 | pan-cancer | AAC | 0.2 | 4e-07 |
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | 0.2 | 6e-07 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.2 | 2e-06 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.29 | 2e-06 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | 0.18 | 5e-06 |